Xcout IntelOnKure Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to OnKure Therapeutics, Inc. among biotech companies — ranked by similarity to what OnKure Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see OnKure Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About OnKure Therapeutics, Inc.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
OnKure Therapeutics, Inc. at a glance
OnKure Therapeutics, Inc. is a biotech company headquartered in Boulder, United States. It is publicly listed (OKUR) with a market capitalisation of $88.1M. Xcout tracks 26 named people at OnKure Therapeutics, Inc., including Nicholas A. Saccomano (President, Chief Executive Officer & Director).
OnKure Therapeutics, Inc. leadership
- Nicholas A. SaccomanoPresident, Chief Executive Officer & Director
- Jason A. LeveroneChief Financial Officer
- Jason LeveroneChief Financial Officer
- Samuel AgrestaChief Medical Officer
- Dylan HartleyChief Scientific Officer
- James BlakeSenior Vice President of Computational Drug Discovery
20 more named people on record for OnKure Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Top 12 OnKure Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to OnKure Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
OncoRock Therapeutics Inc. is a corporation located in Little Rock, Arkansas. The company operates in the life sciences sector, focusing on the research and development of oncology therapeutics.
Similar biotech company
Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a highly selective, orally administered small molecule designed to inhibit AXL. James Bradley Lorens and David R. Micklem established the company on December 21, 2007, and it is based in Bergen, Norway.
Biotechnology
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts. The company is engaged in the research and development of drug candidates for the treatment of human cancers.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotech company
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Biotechnology
IconOVir Bio, Inc. is a preclinical-stage biotechnology company headquartered in New York, United States, with a primary location in San Diego, California. Established in 2020, the venture-backed company is dedicated to pioneering novel oncolytic viral therapies to cure cancer and restore life to patients.
Similar biotech company
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical firm dedicated to the discovery and advancement of epigenetics-based therapies. Its primary focus is on treating cancer and central nervous system (CNS) disorders. The company's pipeline features two lead compounds in Phase II clinical trials: iadademstat (ORY-1001), a selective LSD1 inhibitor targeting oncology, and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for CNS applications, addressing neurological and psychiatric conditions. Furthermore, ORY-3001, another LSD1 inhibitor, is currently in preclinical development for a range of non-cancer-related illnesses. Founded in 2000, Oryzon Genomics S.A. is headquartered in Cornellà de Llobregat, Spain.
Biotechnology
OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical company based in Rockville, Maryland, focused on discovering and developing novel medicines for cancer treatment.
Similar biotech company
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Biotechnology
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Similar biotech company
Oncopeptides is a pharmaceutical company that develops targeted cancer therapies utilizing proprietary platforms like peptide drug conjugates. The company focuses on treating difficult-to-treat hematological diseases and rare cancers, such as multiple myeloma, aiming to provide new treatment options for patients with significant unmet medical needs.
Biotechnology
OverT Bio, Inc. is a New York-based biotechnology company that pioneers next-generation cellular therapies and biologics at scale. The company focuses on developing effective and safe cellular treatments for solid tumors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of OnKure Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for OnKure Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →